Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Good
|
New words:
Abgenix, absence, add, addressing, Alfimeprase, AMG, APIC, Astra, attaining, attributable, attribute, automatically, Bayer, Berlex, beta, BioPharma, broader, budgeting, calculate, calculated, calculation, campaign, Campath, CEO, certiorari, CFO, clearing, comparison, compound, CVP, david, departmental, diffuse, discharge, ditosylate, DLBCL, domestic, dose, ebersman, Eli, Eloxatin, emerging, employment, Exhibit, experimental, exposure, eye, false, fiscal, foreseeable, forma, fractionally, fraudulent, FSP, gain, Genotropin, GlaxoSmithKline, grand, grew, healthcare, Humatrope, hypertonic, illegal, inception, incorrect, individual, induce, inexpensive, inflow, insight, internationally, intervention, john, Johnson, kenalog, Kineret, knowingly, lapatinib, Laser, leasehold, Letter, leukotriene, levinson, liable, Lilly, Macugen, malate, mCRC, merged, moderately, modification, molecular, myeloma, neovascular, Nexavar, nonvested, Nordisk, Norditropin, notably, Novo, Nuvelo, Onyx, Orencia, panitumumab, passed, PDL, peer, pertaining, Pfizer, photocoagulation, point, pool, precisely, prohibit, prompt, promulgated, qui, RA, RCC, reaction, rebate, referral, remuneration, requisite, retaliatory, retiree, retirement, retroactive, retroactively, Saizen, saleable, saline, seal, simplified, slight, solicit, sorafenib, stable, statutory, steroid, stromal, subsidiary, sunitinib, Sutent, tam, Telcyta, Telik, Teva, thereunto, TNF, transformed, Tykerb, typically, unanticipated, Unaudited, undersigned, undertaken, unexercised, unnecessary, unsealed, Visudyne, whiting, wholly, willingly, Xeloda, Xyotax, Zactima, Zeneca
Removed:
absorbed, acceleration, achievement, acknowledging, adding, agency, aim, amend, amortized, angiogenic, arising, assured, beneficiary, biological, biotech, carboplatin, Chiron, Citizen, classified, collaborator, collectibility, commitment, compelling, concluding, Concurrently, consideration, consolidation, Corporation, criteria, deliver, delivered, delivery, denominator, designing, Detail, determinable, developmental, discontinue, dismissed, element, eliminate, endpoint, entirety, entity, estimating, evaluating, evidence, exceeded, excellent, exclusively, exist, failed, FIN, foregoing, fundamental, guaranteed, high, ImClone, immune, impacted, impacting, initiated, interesting, interference, Interpretation, Iressa, leadership, leasing, ledger, life, loan, Lonza, maintenance, manage, marketplace, meeting, met, molecule, move, narrower, nominating, noncontrolling, Nonrefundable, occurring, opportunity, parking, participated, payable, persuasive, preliminary, prepaid, primary, procurement, proforma, Protecting, prove, publicly, rapid, ratably, reallege, receivable, recent, redeclared, referenced, reliable, rent, repair, repay, requested, restructured, restructuring, revision, scheduled, science, separate, size, split, Stakeholder, steadily, substantive, sufficiently, survival, sustainable, synthetic, Taxol, terminated, title, transferable, undelivered, understand, university, validity, variable, warehouse, wide, workshop, XOMA
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 15.1 Letter Regarding Unaudited Interim Financial Information
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
Genentech similar filings
Filing view
External links
EXHIBIT 15.1
April 26, 2006
The Board of Directors and Stockholders of Genentech, Inc.
We are aware of the incorporation by reference in the Registration Statements pertaining to the Genentech, Inc. Tax Reduction Investment Plan, the 2004 Equity Incentive Plan, the 1999 Stock Plan, the 1996 Stock Option/Stock Incentive Plan, the 1994 Stock Option Plan, the 1990 Stock Option/Stock Incentive Plan, and the 1991 Employee Stock Plan, the Registration Statement (Form S-3 No. 333-37072) related to the resale of common shares deliverable upon the exchange of Liquid Yield Option Notes, the Registration Statement (Form S-4 No. 333-128400) related to the exchange offer for Senior Notes, and in the related Prospectuses, as applicable, contained in such Registration Statements of our report dated April 7, 2006 (except Note 7, as to which the date is April 25, 2006), relating to the unaudited condensed consolidated interim financial statements of Genentech, Inc. that are included in its Form 10-Q for the quarter ended March 31, 2006.
Pursuant to Rule 436(c) of the Securities Act of 1933 our report is not a part of the registration statement prepared or certified by accountants within the meaning of section 7 or 11 of the Securities Act of 1933.
Very truly yours, | ||
/s/ERNST & YOUNG LLP |